Dr. Jibran Ahmed
Claim this profileNational Institutes of Health Clinical Center
Studies Pancreatic Cancer
Studies Cancer
7 reported clinical trials
12 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
KRAS positive
BRAF positive
2Cancer
Stage IV
KRAS positive
BRAF positive
Affiliated Hospitals
Clinical Trials Jibran Ahmed is currently running
CA-4948 + Chemotherapy
for Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.
Recruiting1 award Phase 120 criteria
Ceralasertib + Trastuzumab Deruxtecan
for Solid Tumors
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Ceralasertib and trastuzumab deruxtecan may be safe, tolerable and effective in treating patients with advanced solid tumors expressing the HER2 protein or gene.
Recruiting1 award Phase 126 criteria
More about Jibran Ahmed
Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jibran Ahmed has experience with
- Binimetinib
- Fluorouracil
- Oxaliplatin
- Ceralasertib
- Trastuzumab Deruxtecan
- Emavusertib (CA-4948)
Breakdown of trials Jibran Ahmed has run
Pancreatic Cancer
Cancer
Breast cancer
Bile Duct Cancer
Gallbladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jibran Ahmed specialize in?
Jibran Ahmed focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are KRAS positive.
Is Jibran Ahmed currently recruiting for clinical trials?
Yes, Jibran Ahmed is currently recruiting for 3 clinical trials in Bethesda Maryland. If you're interested in participating, you should apply.
Are there any treatments that Jibran Ahmed has studied deeply?
Yes, Jibran Ahmed has studied treatments such as Binimetinib, Fluorouracil, Oxaliplatin.
What is the best way to schedule an appointment with Jibran Ahmed?
Apply for one of the trials that Jibran Ahmed is conducting.
What is the office address of Jibran Ahmed?
The office of Jibran Ahmed is located at: National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States. This is the address for their practice at the National Institutes of Health Clinical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.